Clinical Trial

A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose \[RP2D\]) regimen(s) of JNJ-98768111. The purpose of Part 2 of this study is to find out how safe JNJ-98768111 is at the RP2D regimen(s) in participants with advanced prostate cancer (cancer of the prostate, a male reproductive gland found below the bladder, which has spread extensively to other parts of the body).
Trial Details
NCT Number NCT07746713
Lead Sponsor Janssen Research & Development, LLC
Conditions Prostatic Neoplasms
Enrollment 100 participants
Start Date 2026-08-17
Primary Completion 2029-03-16 (estimated)
Study Completion 2029-03-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-05